Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
|Videos|December 9, 2022
Dr. Antonarakis on available prostate cancer treatments driven by genetic testing
Author(s)Urology Times staff
Advertisement
Emmanuel S. Antonarakis, MD, discusses FDA-approved treatments currently available for prostate cancer that are selected based on genetic testing of patients. Antonarakis is associate director for Translational Research at the University of Minnesota Medical School Masonic Cancer Center, as well as the Clark Endowed Professor of Medicine and director of Genitourinary Oncology in the Department of Medicine’s Division of Hematology, Oncology, and Transplantation
Advertisement
Related to this article
A national study found that use of MRI before prostate biopsy increased in US hospitals from 2017 through the first half of 2026.
The assay is designed to enable faster pathogen identification and susceptibility testing to guide UTI management.
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.
A decision is expected by the fourth quarter of 2026.
Marian Cuello joins to discuss sexual wellness and the importance of normalizing conversations about sexual health for all individuals.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
Advertisement
Advertisement
Trending on Urology Times
1
Evidence for Combining Prostatic Urethral Lift With Radiotherapy
2
FDA grants breakthrough device designation to urine ID/AST panel
3
Use of prebiopsy prostate MRI increasing across US hospitals, study finds
4
Eugene Cone, MD, discusses recombinant BCG in NMIBC
5